Chemed Corporation (CHE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CHE's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CHE Revenue Analysis (2014–2025)
As of March 1, 2026, Chemed Corporation (CHE) generated trailing twelve-month (TTM) revenue of $2.53 billion, reflecting slight decline in growth of -0.1% year-over-year. The most recent quarter (Q4 2025) recorded $639.3 million in revenue, up 2.3% sequentially.
Looking at the longer-term picture, CHE's 5-year compound annual growth rate (CAGR) stands at +4.0%, indicating moderate growth over time. The company achieved its highest annual revenue of $2.53 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows CHE's business is primarily driven by Care Services Total (50%), Routine Home Care (43%), and Inpatient Care (4%).
When compared to Healthcare sector peers including OPCH (+13.0% YoY), ADUS (+23.2% YoY), and AVAH (+11.5% YoY), CHE has underperformed the peer group in terms of revenue growth. Compare CHE vs OPCH →
Peer Comparison
Compare CHE's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CHECurrent | $2.5B | -0.1% | +4.0% | 13.4% | |
| OPCH | $5.6B | +13.0% | +13.3% | 6.0% | |
| ADUS | $1.4B | +23.2% | +13.2% | 9.7% | |
| AVAH | $2.0B | +11.5% | +7.9% | 6.9% | |
| EHAB | $1.0B | +1.0% | - | -11.1% | |
| DCGO | $617M | -47.0% | +66.4% | 4.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.53B | +4.1% | $0 | - | $338.2M | 13.4% |
| 2024 | $2.43B | +7.4% | $854.3M | 35.1% | $366.5M | 15.1% |
| 2023 | $2.26B | +6.1% | $798.8M | 35.3% | $340.6M | 15.0% |
| 2022 | $2.13B | -0.2% | $765.1M | 35.8% | $343.5M | 16.1% |
| 2021 | $2.14B | +2.9% | $769.8M | 36.0% | $343.0M | 16.0% |
| 2020 | $2.08B | +7.3% | $701.4M | 33.7% | $389.7M | 18.7% |
| 2019 | $1.94B | +8.7% | $617.4M | 31.9% | $257.4M | 13.3% |
| 2018 | $1.78B | +7.0% | $555.0M | 31.1% | $243.6M | 13.7% |
| 2017 | $1.67B | +5.7% | $516.2M | 31.0% | $113.0M | 6.8% |
| 2016 | $1.58B | +2.2% | $461.4M | 29.3% | $178.7M | 11.3% |
See CHE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CHE vs AGIO
See how CHE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CHE's revenue growth accelerating or slowing?
CHE revenue growth slowed to -0.1%, below the 5-year CAGR of +4.0%. TTM revenue is $2.5B. The deceleration marks a shift from historical growth rates.
What is CHE's long-term revenue growth rate?
Chemed Corporation's 5-year revenue CAGR of +4.0% reflects the variable expansion pattern. Current YoY growth of -0.1% is near this long-term average.
How is CHE's revenue distributed by segment?
CHE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.